Why did Tonix Pharmaceuticals shares crash 28% lower on Monday?
Jul 26, 2021 · What happened Shares of Tonix Pharmaceuticals ( TNXP -5.62% ) were crashing 28.3% lower as of 10:24 a.m. EDT on Monday. The big decline came after Tonix announced on Friday following the market...
What does Tonix Pharmaceuticals Holding Corp do?
Jul 27, 2018 · Tonix Pharmaceuticals Holding Corp. ( NASDAQ:TNXP) announced this morning that it would be halting its Phase 3 study of its Tonmya drug, which caused its stock price to drop in dramatic fashion. After its twelve-week trial, Tonmya, a drug that treats military-related post-traumatic stress disorder (PTSD), showed “inadequate separation from placebo.”.
What is happening with Tonix Pharmaceuticals Holding Corp (TMP) stock?
Apr 08, 2022 · Tonix Pharmaceuticals Holding Corp. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
What's next for Tonix?
Jul 27, 2018 · Tonix crashes on PhIII PTSD failure, sending stock to the gutter Brittany Meiling After scoring two promising FDA designations on its lead drug, tiny Tonix Pharmaceuticals is …
Why did tonix Pharma stock crash?
After scoring two promising FDA designations on its lead drug, tiny Tonix Pharmaceuticals is aborting its late-stage study in PTSD due to lousy results — nearly flat-lining the company's stock Friday morning.
Is tonix Pharmaceuticals a good stock to buy?
Tonix Pharmaceuticals has received a consensus rating of Buy.
Why was tonix stock so high?
A big regulatory win was reaping huge prizes for Tonix Pharmaceuticals ( TNXP -4.49% ) on Thursday. Following a new nod from the Food and Drug Administration (FDA) for one of its leading pipeline drugs, the biotech's shares went on a quick trip skyward, rising 33% in price on the day.Mar 3, 2022
Will tonix Pharmaceuticals stock rise?
On average, Wall Street analysts predict that Tonix Pharmaceuticals Holding Corp's share price could reach $3.00 by Sep 3, 2021. The average Tonix Pharmaceuticals Holding Corp stock price prediction forecasts a potential upside of 1,239.29% from the current TNXP share price of $0.22.
Will tonix reverse split?
(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it will effect a 1-for-10 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on November 1, 2019.Oct 31, 2019
Will TXMD stock go up?
The average THERAPEUTICSMD stock price prediction forecasts a potential upside of 648.5% from the current TXMD share price of $0.33.
Where is tonix Pharmaceuticals located?
Chatham, New jerseyTonix Pharmaceuticals (Tonix Pharmaceuticals Holding Corp.) is a pharmaceutical company based in Chatham, New jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
Where is Tonix Pharmaceuticals located?
Tonix Pharmaceuticals is based in New York and specializes in producing drugs that treat specific central nervous system conditions. “These results underscore the challenges in designing and conducting well-controlled clinical studies in PTSD, especially military-related PTSD.
Is Tonix halting Phase 3?
Tonix Pharmaceuticals Holding Corp. ( NASDAQ:TNXP) announced this morning that it would be halting its Phase 3 study of its Tonmya drug, which caused its stock price to drop in dramatic fashion.
Is Tonix a Phase 2 drug?
In addition to its Tonmya drug, Tonix is currently working on a bedtime treatment drug for agitation in Alz heimer’s disease, which is currently in its Phase 2 of its trial.
Signals & Forecast
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Tonix Pharmaceuticals Holding Corp.
Support, Risk & Stop-loss
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Is Tonix Pharmaceuticals Holding Corp. stock A Buy?
Tonix Pharmaceuticals Holding Corp. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Insiders are very positive buying more shares than they are selling in Tonix Pharmaceuticals Holding Corp
In the last 100 trades there were 20.56 million shares bought and 10 thousand shares sold. The last trade was done 8 days ago by Lederman Seth who bough 5 million shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. engages in developing medicines for common disorders of the central nervous system. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
What is TNX 102 SL?
Tonmya, also known as TNX-102 SL, had received breakthrough therapy designation from the FDA for its applications in PTSD. And just this month, the agency also handed over fast track status for the drug in a different indication: agitation in Alzheimer’s.
Is Tonix aborting its study?
Brittany Meiling. After scoring two promising FDA designations on its lead drug, tiny Tonix Pharmaceuticals is aborting its late-stage study in PTSD due to lousy results — nearly flat-lining the company’s stock Friday morning. The drug, called Tonmya, apparently failed to improve PTSD symptoms when compared to placebo, ...
What is Tonix Biopharmaceutical?
Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer and autoimmune diseases. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead vaccine candidate, TNX-1800*, is based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects data from animal studies of TNX-1800 in the fourth quarter of this year. TNX-801*, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox and serves as the vector platform on which TNX-1800 is based. Tonix’s lead CNS candidate, TNX-102 SL**, is in Phase 3 development for the management of fibromyalgia. The Company expects results from an unblinded interim analysis in September 2020 and topline data in the fourth quarter of 2020. TNX-102 SL is also in development for agitation in Alzheimer’s disease and alcohol use disorder (AUD). The agitation in Alzheimer’s disease program is Phase 2 ready with FDA Fast Track designation, and the development program for AUD is in the pre-Investigational New Drug (IND) application stage. Tonix‘s programs for treating addiction conditions also include TNX-1300* (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution), which is in Phase 2 development for the treatment of life-threatening cocaine intoxication and has FDA Breakthrough Therapy designation. TNX-601 CR** (tianeptine oxalate controlled-release tablets) is another CNS program, currently in Phase 1 development as a daytime treatment for depression while TNX-1900**, intranasal oxytocin, is in development as a non-addictive treatment for migraine and cranio-facial pain. Tonix’s preclinical pipeline includes TNX-1600** (triple reuptake inhibitor), a new molecular entity being developed as a treatment for PTSD; TNX-1500* (anti-CD154), a monoclonal antibody being developed to prevent and treat organ transplant rejection and autoimmune conditions; and TNX-1700* (rTFF2), a biologic being developed to treat gastric and pancreatic cancers.
What is TNX-1800?
TNX-801*, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox and serves as the vector platform on which TNX-1800 is based.
What is the immunology portfolio?
The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer and autoimmune diseases. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.
When is the SEC filing for 2020?
Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (the “SEC”) on March 24, 2020, and periodic reports filed with the SEC on or after the date thereof.
When will Tonix start testing for PTSD?
Tonix previously noted that it may begin a late-stage study for PTSD in the first quarter of 2017. This remains a large risk, but there have effectively not been new treatments for PTSD for a decade and a half.
How many people have PTSD?
About 3.6% of U.S. adults aged 18 to 54 (5.2 million people) have PTSD during the course of a given year.
Is Tonix a late stage company?
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) was the disaster of the day on Tuesday after the company announced that it will stop development of its fibromyalgia treatment after it failed in a late-stage trial.
Is Tonix a cure for fibromyalgia?
Fibromyalgia is a chronic disorder that causes musculoskeletal pain, as well as fatigue and sleep disturbances. It has no current cure and the current treatments target symptoms. Quite simply, Tonix showed that the drug candidate did not meet its primary pain reduction target by 30% or more over a 12-week period.
1 TNXP Stock's Price Graph & Average Annual Return
Below is a graph showing closing prices of Tonix Pharmaceuticals Holding Corp (TNXP) for the past 10 years. The below chart uses adjusted close instead of market close prices. (Adjusted close factors in corporate or institutional level actions outside the market.)
2 How Tonix Pharmaceuticals Holding Corp (TNXP) Stock Performed Against The Entire Stock Market
You should not evaluate a stock in isolation. Rather, you will benefit more if you assess the performance against broad indices and similar stocks.
4 10 Biggest One-Day Losses
Let us now see 10 biggest one-day losses of Tonix Pharmaceuticals Holding Corp (TNXP) stock.
Conclusion
Hopefully, the above report helps you learn about the past ten-year performance of Tonix Pharmaceuticals Holding Corp (TNXP) shares. Kindly use the sections below to suggest corrections or improvements to the report.
Want to become a smart investor?
Netcials reports section helps you with deep insights into the performance of various assets over the years. We are constantly upgrading and updating our reports section. Feel free to access them. Do not forget to leave your feedback.
